

ENVIRONMENTAL PROTECTION AGENCY

June 4, 2010, make the following correction:

40 CFR Part 52

§52.420 [Corrected]

[EPA-R03-OAR-2010-0039; FRL-9158-3]

On page 31712 in §52.420, the table titled EPA-APPROVED REGULATIONS IN THE DELAWARE SIP should appear as follows:

Approval and Promulgation of Air Quality Implementation Plans; Delaware; Control of Nitrogen Oxide Emissions From Industrial Boilers and Process Heaters at Petroleum Refineries

Correction

In rule document 2010-13377 beginning on page 31711 in the issue of

EPA-APPROVED REGULATIONS IN THE DELAWARE SIP

State citation	Title/subject	State effective date	EPA approval date	Additional explanation
*	*	*	*	*
Regulation 1142—Specific Emission Control Requirements (Formerly Regulation No. 42)				
*	*	*	*	*
Section 2.0	Specific Emission Control Requirements.	11/11/09	6/4/10 [Insert page number where the document begins].	Emission limitations for any industrial boiler or process heater with a maximum heat input capacity of equal to or greater than 200 mmBTU/hr.
*	*	*	*	*

[FR Doc. C1-2010-13377 Filed 6-9-10; 8:45 am]
BILLING CODE 1505-01-D

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 417, 422, 423, and 480

[CMS-4085-CN]

RIN 0938-AP77

Medicare Program; Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; Corrections

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Correction of final rule.

SUMMARY: This document corrects technical and typographical errors in the final rule that appeared in the April 15, 2010 **Federal Register** entitled “Medicare Program; Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs.”

DATES: Effective Date: This correction notice is effective June 7, 2010.

FOR FURTHER INFORMATION CONTACT: Alissa Deboy, (410) 786-6041.

SUPPLEMENTARY INFORMATION:

I. Background

In the final rule entitled “Medicare Program; Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs” which appeared in the April 15, 2010 **Federal Register** (FR Doc. 2010-7966, (75 FR 19678)), there were technical and typographical errors that are identified and corrected in the Correction of Errors section below. The provisions in this correction notice are effective as if they had been included in the document that appeared in the April 15, 2010 **Federal Register**. Accordingly, the corrections are effective June 7, 2010.

II. Summary of Errors

On page 19752, in our preamble discussion regarding risk adjustment data validation (RADV) appeals and the addition of Medicare Advantage (MA) organization RADV—dispute and appeal procedures we made typographical errors in two regulatory citations and we correct these errors in section IV.A.1. of

this correction notice. In addition, on page 19809 in the regulations text for the RADV provisions, we inadvertently designated two paragraphs as § 422.311(c)(iii)(C). We are correcting this error in section IV.B.1. of this correction notice.

In our preamble discussion of criteria and procedures for identifying “protected classes” of drugs within which all covered Part D drugs must be included in Part D formularies (75 FR 19767), we indicated that we would not finalize in regulations (§ 423.100) our proposed definitions used to interpret the section 176 of Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) criteria (that is, the definitions for the terms, “drug category or class,” “major or life threatening clinical consequences,” “restricted access,” and “significant need for access to multiple drugs”). However, we indicated that we would finalize our proposed regulations text regarding the exceptions criteria (§ 423.120(b)(2)(iv)). Therefore, in section IV.B.3. and 4. of this correction notice, we correct these errors by removing the proposed definitions inadvertently published for § 423.100 and adding the exceptions criteria that were inadvertently omitted from § 423.120(b).